Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03529175

Scheduling Nab-paclitaxel With Gemcitabine — SIEGE  

Pancreatic Adenocarcinoma Metastatic Clinical Trial

Official title:
Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Trial Summary

Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine. However, a large international trial showed that combining gemcitabine with a drug called nab-paclitaxel (or abraxane) was more effective compared with gemcitabine alone. The purpose of this study is to compare two different ways of combining gemcitabine with abraxane. Conventionally, both drugs are given on the same day via a drip into a vein in the arm but research suggests that giving abraxane 24 hours in advance of gemcitabine could possibly be more beneficial.

In this study, blood and tumour samples will be collected and analysed to try to confirm what has been seen in the laboratory studies. In addition, the investigators wish to find out whether certain tumour characteristics (called biomarkers) can be used to predict for response to chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03529175
Study type Interventional
Source Cambridge University Hospitals NHS Foundation Trust
Contact
Status Completed
Phase Phase 2
Start date January 2014
Completion date June 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT06006728 - Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
Terminated NCT03213626 - Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05077800 - FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Phase 2
Completed NCT01715142 - Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer Early Phase 1
Completed NCT02179970 - To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Phase 1
Completed NCT02195180 - Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma Phase 2
Recruiting NCT06051851 - Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03633734 - Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT05360264 - tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr Phase 2
Recruiting NCT04150042 - SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells Phase 1
Withdrawn NCT03127124 - QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT06076837 - The Seven Trial: Exploiting the Unfolded Protein Response Phase 1
Recruiting NCT06396637 - PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC Phase 2
Completed NCT01053013 - Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer Phase 2